Parkinson's drug looking good
Parkinson’s drug looking good
Although drugs to treat Parkinson’s disease have been few and far-between, the approval of Mirapex could help to change all that, says Paul Maestrone, MD, director of scientific and medical affairs at the Staten Island, NY-based American Parkinson’s Disease Association. SmithKline Beecham’s dopamine-agonist, ropinirole, has performed well in recent clinical trials and could be on its way to winning FDA clearance. (See DSM, July 1997, pp. 87-88.) And two other drugs, from Hoffman-LaRoche of Nutley, NJ, and Novartis, are currently under consideration at the FDA, Maestrone notes.
[For more information about Mirapex, contact Pharmacia & Upjohn at (800) 821-7000.]
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.